The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1028
ISSUE1028
June 5, 1998
Clopidogrel for Reduction of Atherosclerotic Events
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Clopidogrel for Reduction of Atherosclerotic Events
June 5, 1998 (Issue: 1028)
Clopidogrel bisulfate (Plavix - Bristol-Myers Squibb/Sanofi), a new thienopyridine antiplatelet agent similar to ticlopidine (Ticlid - Medical Letter, 34:65, 1992), has been approved by the US Food and Drug Administration (FDA) for secondary...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.